Lipid Controls
Avanti Polar Lipids EGG YOLK PHOSPHOTIDYL CHOLINE
L- alpha -Phosphatidylcholine (Egg, Chicken). 97281-44-2
![Avanti Polar Lipids 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), 474922-82-2, MFCD02262246, 25mg](https://assets.fishersci.com/TFS-Assets/CCG/product-images/VN00054318-00037-25G.JPG-250.jpg)
Avanti Polar Lipids 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), 474922-82-2, MFCD02262246, 25mg
Formula Weight: 2693.285, Purity >99%, Storage Temperature: -20°C.
Avanti Polar Lipids 14:0 PC IN CHLOROFORM, 25MG
1,2-dimyristoyl-sn-glycero-3-phosphocholine. 18194-24-6
eMolecules BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
Avanti Polar Lipids 16:0 PEG2000 PE | 474922-84-4 | MFCD02262261 | 25mg
16:0 PEG2000 PE | Purity: 99% | Mol Wt: 2749.42 | 474922-84-4 | MFCD02262261 | 25mg
![Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000385579-logo.png-250.jpg){kind=logo}
Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG
DSPE-PEG (2000)-COOH is a pegylated derivative of 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine. This compound is capable of forming micelles for targeted drug delivery.
- Can form micelles for targeted drug delivery
- Useful for polyvalent targeted delivery of vinorelbine to cancer cells
- Can be used as optical coherence tomography contrast agents for tumor angiography in live animals
- Targets liposome
- Pathway: Metabolic enzyme/protease
- Powder stable at -20°C for 3 years
- In solvent stable at -80°C for 6 months, and at -20°C for 1 month
- Solubility in H2O: 25 mg/mL (requires ultrasonic treatment)
- Solubility in DMSO: 25 mg/mL (requires ultrasonic, warming, and heating to 60°C)
- Achieves a clear solution at ≥ 2.5 mg/mL in specific in vivo solvent combinations
- For research use only
Cayman Chemical L-319, Purity: ≥95%, CAS: 1351586-50-9, 25 mg
An ionizable cationic (pKa = 6.38) and biodegradable lipid derivative of DLin-MC3-DMA; has been used in the formation of LNPs; administration of mouse FVII-targeting siRNA in L-319-containing LNPs reduce serum levels of FVII in mice; LNPs containing L-319 in combination with cKK-E12 and encapsulating VZV mRNA encoding gE increase the lymph node and spleen levels of CD11c+CD80+ and CD11c+CD86+ cells and total serum IgG titers in mice, as well as decrease the number of VZV-induced rashes and the epithelial levels of VZV DNA, in a guinea pig model of VZV-induced shingles
Avanti Polar Lipids 18:0 PEG2 PE IN POWDER,1G18:0
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt). 474922-77-5
Avanti Polar Lipids 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | 26853-31-6 | 760.1 g/mol | 25MG
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | 26853-31-6 | 760.1 g/mol | 25MG
Medchemexpress LLC D-Lin-MC3-DMA | 1224606-06-7 | MFCD31657426 | 50 mg
D-Lin-MC3-DMA | Purity: ≥98.0% | Mol Wt: 642.102 | 1224606-06-7 | MFCD31657426 | 50 mg